Skip to main content

Diagnosis and Management of Polycystic Ovary Syndrome (PCOS)

  • Chapter
Endocrinology and Diabetes

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women (5–15 %). All PCOS definitions include hyperandrogenism and oligo/anovulation in the proposed diagnostic criteria. Polycystic ovary morphology on ultrasound was not part of the initial definition and is not considered necessary for diagnosis if the patient meets the other two criteria. PCOS remains a diagnosis of exclusion and other disorders which are associated with symptoms/signs of androgen excess in women must be excluded. The clinical expression of PCOS is variable with hirsutism representing the most common clinical manifestation (65–75 %). Moreover, there is a strong link between PCOS and metabolic syndrome manifestations, including obesity, insulin resistance, type 2 diabetes mellitus (T2DM), dyslipidaemia, hypertension and non-alcoholic fatty liver disease (NAFLD). PCOS women exhibit increased incidence of obesity (30–75 %) and central adiposity even within the normal BMI range (50–70 %). In the spectrum of PCOS phenotypes, presence of hyperandrogenism is associated with a more adverse cardiometabolic profile, whereas menstrual irregularity and polycystic ovary morphology are more closely linked to infertility problems. Oral contraceptives are recommended as first-line treatment for hirsutism/acne in PCOS. Lifestyle modifications for weight loss are also essential in overweight/obese PCOS women. Metformin therapy may improve metabolic and reproductive outcomes in selected PCOS women and is recommended in PCOS patients with T2DM or impaired glucose tolerance who are failing lifestyle modification. Clomiphene citrate is mainly used for ovulation induction in anovulatory PCOS women without other infertility factors. The long-term management plan for the care of PCOS women must include regular screening and follow-up in order to prevent, diagnose and treat T2DM, cardiovascular risk factors, NAFLD, obstructive sleep apnea, eating disorders, depression/anxiety, endometrial hyperplasia/cancer and pregnancy complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al.; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.

    Google Scholar 

  2. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.

    Article  CAS  PubMed  Google Scholar 

  3. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012;18(2):146–70.

    Article  CAS  PubMed  Google Scholar 

  4. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.e25.

    Article  PubMed  Google Scholar 

  5. Kyrou I, Randeva H, Weickert MO. Clinical problems caused by obesity. In: Weickert MO, editor. Obesity-Obesitext at Endotext.org, MDTEXT.COM, INC, S. Dartmouth; 2014. (http://www.endotext.org/section/obesity/).

  6. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92.

    Google Scholar 

  7. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–20.

    Article  CAS  PubMed  Google Scholar 

  8. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012;33(5):812–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

    Article  Google Scholar 

  10. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;(5):CD003053.

    Google Scholar 

  11. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, et al.; Guideline Development Groups. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011;195(6):S65–112.

    Google Scholar 

  12. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038–49.

    Article  CAS  PubMed  Google Scholar 

  13. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications; 1992;377–384.

    Google Scholar 

  14. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–45.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Harpal Singh Randeva MBChB, PhD, FRCP .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Kyrou, I., Weickert, M.O., Randeva, H.S. (2015). Diagnosis and Management of Polycystic Ovary Syndrome (PCOS). In: Ajjan, R., Orme, S. (eds) Endocrinology and Diabetes. Springer, London. https://doi.org/10.1007/978-1-4471-2789-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2789-5_13

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2788-8

  • Online ISBN: 978-1-4471-2789-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics